Top 5 Services Companies To Buy For 2015

Top 5 Services Companies To Buy For 2015: Arch Therapeutics Inc (ARTH)

Arch Therapeutics, Inc. (Arch), formerly Almah, Inc., incorporated on September 16, 2009, operates as a life science company developing polymers containing peptides intended to form gel-like barriers over wounds to stop or control bleeding. Arch is a medical device company offering an approach to the rapid cessation of bleeding (hemostasis) and control of fluid leakage (sealant) during surgery and trauma care. Arch's products are in preclinical development. The first product, AC5, is designed for hemostasis in minimally invasive (laparoscopic) and open surgical procedures.

AC5

AC5 is a synthetic peptide consisting of naturally occurring amino acids. When squirted or sprayed onto a wound, AC5 intercalates into the nooks and crannies of the connective tissue where it builds itself into a physical, mechanical structure. That structure provides a barrier to leaking substances, including blood and other bodily fluids, regardless of type of surgery or , based on early data, clotting ability.

Advisors' Opinion:

• [By James E. Brumley]

  To give credit where it's due, Cytomedix, Inc. (OTCBB:CMXI) and Baxter International Inc. (NYSE:BAX) have both helped shape the landscape of the hemostasis (bleeding control) market with their products, AutoloGel and TISSELL, respectively. Arch Therapeutics Inc. (OTCBB:ARTH) has proverbially taken their concepts "up a notch", however, and its direct solution to a problem that CMXI and BAX can't quite solve may make ARTH the hottest trading candidate in the hemostasis space.

• [By John Udovich]

  Laparoscopic surgery or minimally invasive surgery (MIS) is a type of surgical technique where operations in the abdomen are performed through small incisions while small cap stocks ArthroCare Corporation (NASDAQ: ARTC), EDAP TMS S.A. (NASD! AQ: EDAP), SafeStitch Medical Inc (OTCBB: SFES) and Arch Therapeutics Inc (OTCBB: ARTH) are all in some way focused on aiding minimally invasive procedures. According to a 2012 report produced by MedMarket Diligence, LLC, approximately 114 million surgical and procedure-based wounds occur annually worldwide, including 36 million in the US, and perhaps up to a quarter of these procedures can be described as laparoscopic in nature. Moreover, use of the technique is bound to increase as it reduces pain and hemorrhaging plus leads to a shorter recovery time.

• [By John Udovich]

  Small cap stocks Derma Sciences Inc (NASDAQ: DSCI), Oculus Innovative Sciences, Inc (NASDAQ: OCLS) and Arch Therapeutics Inc (OTCBB: ARTH) specialize or have a focus on wound care – a medical problem that has plagued mankind since the dawn of time. After all and think back to our Civil War when disease along with infections resulting from improper wound care probably killed more soldiers than actual battles. Even today, infection after surgery or after receiving a wound or injury of any kind is still a constant threat. And then there is the scaring that can result from any sort of invasive surgery or injury. With those thoughts in mind, here are three small cap wound care stocks trying address these problems:

source from Top Stocks For 2015:http://www.topstocksblog.com/top-5-services-companies-to-buy-for-2015.html